Click Therapeutics has appointed Randall Kaye to serve as its chief medical officer. Kaye comes to Click from SSI Strategy, where he was chief scientific officer. New York-based Click also appointed Austin Speier to serve as chief strategy officer. Speier was previously vice president of emerging technologies at Precision for Medicine. Click is developing software … Continue reading “Click Therapeutics Adds Randall Kaye, Austin Speier to C-Suite”
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
NGM Biopharma Promotes Woodhouse to CEO, Trombley to President
David Woodhouse has been appointed CEO of NGM Biopharmaceuticals. Woodhouse was also elected to the South San Francisco, CA, company’s board of directors. He succeeds William Rieflin, who will remain on NGM’s board and take on the role of executive chairman. Woodhouse was previously NGM’s chief financial officer. He joined NGM in 2015 from Goldman … Continue reading “NGM Biopharma Promotes Woodhouse to CEO, Trombley to President”
Menlo’s Drug Fails Again in Clinical Trials, This Time for Chronic Cough
A Menlo Therapeutics drug developed to treat chronic cough has failed to beat a placebo in a mid-stage study, and the clinical-stage company is stopping work on that drug program. It’s the second time in six months that the drug, serlopitant, has failed in clinical trials. In April, Redwood City, CA-based Menlo (NASDAQ: [[ticker:MNLO]]) announced … Continue reading “Menlo’s Drug Fails Again in Clinical Trials, This Time for Chronic Cough”
SQZ Biotech Appoints Pfizer Veteran Volker Herrmann COO
Volker Herrmann has been appointed chief operating officer and president of cell therapy developer SQZ Biotechnologies. Before joining Watertown, MA-based SQZ, Herrmann was chief operating officer of Selenity Therapeutics. His experience also includes 17 years at Pfizer (NYSE: [[ticker:PFE]]), where he held various positions, including head of global strategy, marketing, and commercial for the company’s … Continue reading “SQZ Biotech Appoints Pfizer Veteran Volker Herrmann COO”
BioClin Chairman Scott Myers Adds CEO Role
Scott Myers, chairman of BioClin Therapeutics, has been appointed CEO of the San Leandro, CA, company. Myers has been chairman of BioClin since June. The company says Myers will continue in his role as chairman. Myers most recently served as CEO of Seattle-based Cascadian Therapeutics, an oncology company that was acquired by Seattle Genetics (NASDAQ: … Continue reading “BioClin Chairman Scott Myers Adds CEO Role”
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More
Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars in research, led to a vast matrix of clinical trials, and started to change the way how several cancers are treated. The reason: When it works, cancer immunotherapy can lead to longer-lasting … Continue reading “Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant’s IPO & More”
Guardant Health’s IPO Tops Range, Raising $238M for Cancer Tests
Guardant Health continued the rapid drumbeat of life science IPOs this year by raising $237.5 million in its stock market debut, making it one of the biggest IPOs so far this year. The cancer diagnostics company priced its offering of 12.5 million shares at $19 apiece late Wednesday, well above the $15 to $17 per … Continue reading “Guardant Health’s IPO Tops Range, Raising $238M for Cancer Tests”
Second Genome Promotes Karim Dabbagh to President & CEO
Karim Dabbagh has been appointed president and CEO of microbiome drug developer Second Genome. Dabbagh is also joining the South San Francisco, CA, company’s board of directors. He succeeds Glenn Nedwin, who retired last month. Dabbagh has been Second Genome’s chief scientific officer since 2014. Before joining the company, Dabbagh was vice president and head … Continue reading “Second Genome Promotes Karim Dabbagh to President & CEO”
Pfizer Veteran Bernard Fermini Joins Novoheart as Chief R&D Officer
Novoheart (TSXV: [[ticker:NVH]]) has appointed Bernard Fermini to serve as chief research and development officer of the Vancouver, BC, stem cell biotechnology company. Fermini most recently worked at Coyne Scientific, where he was vice president of safety and toxicology and chief scientific officer. His experience also includes 17 years at Pfizer (NYSE: [[ticker:PFE]]), where he … Continue reading “Pfizer Veteran Bernard Fermini Joins Novoheart as Chief R&D Officer”
Paratek Wins Two FDA Drug Approvals for Three Conditions in Same Day
Yesterday was a good day for Paratek Pharmaceuticals. The FDA approved a Paratek antibiotic as a treatment for pneumonia and serious skin infections. That regulatory decision late Tuesday for the drug, omadacycline (Nuzyra), followed approval earlier that day for a different drug, sarecycline (Seysara), a treatment for moderate-to-severe acne. The stock price of Boston-based Paratek (NASDAQ: … Continue reading “Paratek Wins Two FDA Drug Approvals for Three Conditions in Same Day”
Synlogic Promotes Aoife Brennan to President & CEO
Aoife Brennan has been appointed president and CEO of synthetic biology company Synlogic (NASDAQ: [[ticker:SYBX]]), effective immediately, the company announced Tuesday. Brennan had been serving as interim president and chief executive of Cambridge, MA, Synlogic since May. She joined the company as chief medical officer in 2016 after six years at Biogen (NASDAQ: [[ticker:BIIB]]). Synlogic … Continue reading “Synlogic Promotes Aoife Brennan to President & CEO”
ORIC Pharmaceuticals Names Pratik Multani Chief Medical Officer
Pratik Multani has been appointed chief medical officer of South San Francisco, CA-based ORIC Pharmaceuticals. Multani was most recently chief medical officer of Ignyta, a San Diego biotech that was acquired by Roche in a $1.7 billion deal last year. ORIC—which stands for “overcoming resistance in cancer”—develops drugs for cancers that have become resistant to … Continue reading “ORIC Pharmaceuticals Names Pratik Multani Chief Medical Officer”
Pivot Bio Gets $70M, Led by Bill Gates’s Fund, to Replace Fertilizer
Applying fertilizers to fields has been a standard farming practice for generations. The problem with these chemicals is that they end up in the air or in water runoff. Scientists at agriculture startup Pivot Bio say the key to delivering an important nutrient to crops has been at the plants’ roots all along—and the company … Continue reading “Pivot Bio Gets $70M, Led by Bill Gates’s Fund, to Replace Fertilizer”
Albert Bourla Named Successor to Pfizer CEO Ian Read
Pfizer (NYSE: [[ticker:PFE]]) CEO Ian Read will step away from the company’s top job at the end of the year and become executive chairman of its board of directors, the company announced Monday. Albert Bourla, currently Pfizer’s chief operating officer, has been elected by the board to serve as the company’s CEO. The changes for … Continue reading “Albert Bourla Named Successor to Pfizer CEO Ian Read”
VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic
VelosBio, a biotech startup researching new cancer drugs, has raised $58 million in financing. The new VelosBio cash, a Series A round of financing, was led by Arix Bioscience (LSE: [[ticker:ARIX]]) and Sofinnova Ventures. VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The company is developing antibody drug conjugates, a class … Continue reading “VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic”
NodThera Picks Genzyme Exec Adam Keeney for President and CEO Role
Adam Keeney has joined NodThera as president and CEO. He is also joining the company’s board of directors. Alan Watt, who had been serving as interim CEO, will resume his role as chief scientific officer of the Cambridge, UK, company. With Keeney’s appointment, NodThera will also open a new office in the Boston area. Keeney … Continue reading “NodThera Picks Genzyme Exec Adam Keeney for President and CEO Role”
GSK’s Hogenhuis Joins Ultragenyx Pharma as Chief Operating Officer
Wladimir Hogenhuis has been appointed chief operating officer of Novato, CA-based Ultragenyx Pharmaceutical (NASDAQ: [[ticker:RARE]]). Hogenhuis comes to the rare disease drug developer from GlaxoSmithKline (NYSE: [[ticker:GSK]]), where he was senior vice president and general manager, specialty franchise. In April, Ultragenyx won FDA approval for burosumab (Crysvita), a drug developed to treat the rare bone … Continue reading “GSK’s Hogenhuis Joins Ultragenyx Pharma as Chief Operating Officer”
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines
[Updated, 9/28/18, 12:54 p.m. See below.] An Eli Lilly drug developed to prevent migraine headache pain before it starts has won FDA approval. The FDA decision announced late Thursday marks the third drug in this new class of medicines to receive the regulatory nod this year. Two weeks ago, the FDA approved a migraine drug … Continue reading “Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines”
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
The window for life science IPOs is still open, and five biotechs and one medical device company chose the last week of the third quarter to make their stock market debuts. Gritstone Oncology (NASDAQ: [[ticker:GRTS]]) closed out the week by raising $100 million in an upsized IPO. On Thursday night, Emeryville, CA-based Gritstone priced its … Continue reading “Six Life Science Firms Close Q3 with an IPO, More Are on the Way”
Eli Lilly Strikes Deal for Diabetes Pill to Gain on Novo Nordisk
Eli Lilly has a blockbuster diabetes drug, dulaglutide (Trulicity), which helps the body make more insulin. But that drug, and others in the same class, are injectables. A number of companies are trying to offer patients a pill alternative. Lilly (NYSE: [[ticker:LLY]]) now has a new pill drug candidate in its pipeline. The Indianapolis pharmaceutical … Continue reading “Eli Lilly Strikes Deal for Diabetes Pill to Gain on Novo Nordisk”
Geron’s Drug Alliance with Janssen Terminated, Shares Plummet 68%
Four years after Geron landed a pharmaceutical partner to co-develop its lead drug, the Menlo Park, CA, biotech is now moving forward with the compound on its own. Janssen Biotech is ending the collaboration with Geron on imetelstat, a drug that had reached mid-stage clinical trials as a treatment for blood disorders. The Johnson & … Continue reading “Geron’s Drug Alliance with Janssen Terminated, Shares Plummet 68%”
LogicBio Jumps on the Gene Therapy 2.0 Wave and Lines Up an IPO
Another gene therapy company is on its way to the public markets. But this one, LogicBio Therapeutics, is part of a newer crop of gene therapy developers that aim to overcome the potential shortcomings of the treatments on the market or in human trials. LogicBio’s technology is still preclinical, but the company aims to start … Continue reading “LogicBio Jumps on the Gene Therapy 2.0 Wave and Lines Up an IPO”
Former Alnylam Exec Jared Gollob Named Kymera Chief Medical Officer
Jared Gollob has been appointed chief medical officer of Cambridge, MA-based Kymera Therapeutics. Gollob most recently worked at Alnylam Pharmaceuticals (NASDAQ: [[ticker:ALNY]]) where he was vice president of clinical development and global vice president of medical affairs. Kymera is developing drugs based on protein degradation, the process cells use to rid themselves of harmful proteins.
Genentech Executive Jason Ehrlich Joins Kodiak Sciences C-Suite
Kodiak Sciences, a Palo Alto, CA, eye drug developer, has appointed Jason Ehrlich to serve as chief medical officer and chief development officer. Ehrlich comes to Kodiak from Roche subsidiary, Genentech, where he was global head, clinical ophthalmology. Recently, Kodiak filed for an IPO to finance clinical trials testing its lead drug, KSI-301, in patients … Continue reading “Genentech Executive Jason Ehrlich Joins Kodiak Sciences C-Suite”
Two Gemphire Execs Caught in Layoffs After Clinical Trial Setbacks
Gemphire Therapeutics is laying off five, including two executives, as the company grapples with clinical trial setbacks for its lead drug candidate. Chief Financial Officer Jeffrey Mathieson and Chief Medical Officer Lee Golden have left Livonia, MI-based Gemphire (NASDAQ: [[ticker:GEMP]]), though the company says Mathieson agreed to consult with the company on financial and accounting … Continue reading “Two Gemphire Execs Caught in Layoffs After Clinical Trial Setbacks”
Former Kite Pharma Exec Anthony Polverino Named Zymeworks CSO
Anthony Polverino has been appointed executive vice president of early development and chief scientific officer of Vancouver, BC-based Zymeworks (NYSE: [[ticker:ZYME]]). Polverino most recently worked at Kite Pharma, where he was interim chief scientific officer, and prior to that, vice president of research. Kite was acquired by Gilead Sciences (NASDAQ: [[ticker:GILD]]) last year. Zymeworks develops … Continue reading “Former Kite Pharma Exec Anthony Polverino Named Zymeworks CSO”
Adrian Jubb Departs Achaogen for Immune-Onc Chief Medical Post
Adrian Jubb has been appointed chief medical officer of Palo Alto, CA-based Immune-Onc Therapeutics. Jubb comes to Immune-Onc from Achaogen (NASDAQ: [[ticker:AKAO]]), where he was vice president and head of early development. Immune-Onc also appointed An Song to serve as senior vice president of development sciences. Song most recently worked at Genentech as a senior … Continue reading “Adrian Jubb Departs Achaogen for Immune-Onc Chief Medical Post”
Alexion Hits Study Goals, Could Expand Blockbuster Drug to CNS
Alexion Pharmaceuticals’ flagship drug has made a strong case it can treat yet another rare disease, and the company is now mapping out plans to file for approval in the U.S. and other regions. The Boston company released preliminary Phase 3 data for eculizumab (Soliris) as a treatment for neuromyelitis optica spectrum disorder (NMOSD), a … Continue reading “Alexion Hits Study Goals, Could Expand Blockbuster Drug to CNS”
SR One’s Brian Gallagher Jumps to Abingworth for Partner Post
Brian Gallagher is joining London-based Abingworth as a partner based in the life sciences investment firm’s Boston office. Gallagher comes to Abingworth from SR One, the venture capital arm of GlaxoSmithKline (NYSE: [[ticker:GSK]]), where was a partner. Before SR One, Gallagher was senior director of corporate development at Sirtris Pharmaceuticals, which was acquired by GSK … Continue reading “SR One’s Brian Gallagher Jumps to Abingworth for Partner Post”
Portola Pharma Picks Scott Garland to Succeed Bill Lis as CEO
Scott Garland will become president and CEO of Portola Pharmaceuticals (NASDAQ: [[ticker:PTLA]]) effective Oct. 8. Garland will also join the South San Francisco, CA, company’s board of directors. Garland is coming to Portola from Redwood City, CA-based Relypsa, where he has served as president, and prior to that, chief commercial officer. Portola began looking for … Continue reading “Portola Pharma Picks Scott Garland to Succeed Bill Lis as CEO”
Y-mAbs Upsizes IPO, Gets $96M to Test Two Pediatric Cancer Drugs
Cancer drug developer Y-mAbs Therapeutics is the latest biotech company to go public, raising $96 million in its IPO. New York-based Y-mAbs priced its offering of 6 million shares at $16 each, which was the high end of its projected range. The company had planned to sell 5.3 million shares priced at $14 to $16 … Continue reading “Y-mAbs Upsizes IPO, Gets $96M to Test Two Pediatric Cancer Drugs”
Microbiome Startup uBiome Expands into Drug Research with $83M
Biotech company uBiome started as a “citizen science” project that collected and studied microbiome samples in order to learn how the trillions of bacteria living in and on people’s bodies affect human health. Six years and 250,000 samples later, uBiome is now moving beyond simply helping people understand their microbiomes. The San Francisco company has … Continue reading “Microbiome Startup uBiome Expands into Drug Research with $83M”
Elanco IPO Raises $1.5B as the Animal Health Biz Spins Off from Lilly
Elanco is now a standalone company after raising $1.5 billion in its stock market debut. Greenfield, IN-based Elanco (NYSE: [[ticker:ELAN]]) sold 62.9 million shares at $24 apiece, which topped the $20 to $23 range it had initially targeted. Investors showed their appetite for the animal health company, driving its stock price up more than 39 … Continue reading “Elanco IPO Raises $1.5B as the Animal Health Biz Spins Off from Lilly”
Aduro Biotech’s Chief Medical Officer Sacks to Resign in October
Natalie Sacks will resign from her position as chief medical officer of Aduro Biotech (NASDAQ: [[ticker:ADRO]]) effective Oct. 1, the cancer immunotherapy developer announced Wednesday. Berkeley, CA-based Aduro gave no reason for the resignation, but said that Sacks will continue to advise the company through a consulting agreement. Sacks joined Aduro in 2016. Last year, … Continue reading “Aduro Biotech’s Chief Medical Officer Sacks to Resign in October”
Aegerion’s Jeffrey Bloss Joins Tarveda as Chief Medical Officer
Jeffrey Bloss has been appointed chief medical officer of Tarveda Therapeutics. Bloss comes to Watertown, MA-based Tarveda from Aegerion Pharmaceuticals, where he was chief medical officer and senior vice president, medical affairs. His experience includes senior roles at Astellas Pharma (OTCMKTS: [[ticker:ALPMY]]), GlaxoSmithKline (NYSE: [[ticker:GSK]]), Genentech, and Eli Lilly (NYSE: [[ticker:LLY]]). Last year, Tarveda raised … Continue reading “Aegerion’s Jeffrey Bloss Joins Tarveda as Chief Medical Officer”
Indigo Adds $250M as It Expands Reach Into Agricultural Supply Chain
Indigo Ag started as a company focused on microbial agriculture—finding microorganisms to develop into seed coatings intended to boost crop yields. While microbiology remains a focus, CEO David Perry says the startup is positioning itself to take on additional aspects of the agriculture business. Boston-based Indigo is revealing one of the ways it aims to … Continue reading “Indigo Adds $250M as It Expands Reach Into Agricultural Supply Chain”
CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy
ViaCyte’s attempts to develop a stem cell therapy for diabetes have been stymied by the immune system, which recognizes the implanted cells as foreign. Meanwhile, CRISPR Therapeutics has found success in gene-editing cells so that the cells avoid such immune responses. Now the two companies are combining their respective technologies to develop a stem cell-based … Continue reading “CRISPR, ViaCyte Team Up to Develop Stem Cell-Based Diabetes Therapy”
Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s
A Teva Pharmaceutical migraine-prevention drug has won FDA approval, the second therapy in this new drug class to receive the regulatory nod this year. The Friday approval for the Teva (NYSE: [[ticker:TEVA]]) drug fremanezumab (Ajovy) came a little earlier than expected; the target date for the FDA decision was Sept. 16. The drug is part … Continue reading “Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s”
Former Pfenex Exec Chen Joins Metacrine as Chief Medical Officer
Hubert Chen has been appointed chief medical officer of San Diego biotech Metacrine. Chen most recently worked as chief medical officer of Pfenex (NYSE American: [[ticker:PFNX]]). Metacrine develops drugs for liver and gastrointestinal diseases. Last year, Metacrine raised $22 million in Series B financing. The company plans to test its lead drug, MET409, as a … Continue reading “Former Pfenex Exec Chen Joins Metacrine as Chief Medical Officer”
Suono Bio Names Lisa Ricciardi CEO, Carl Schoellhammer Becomes COO
Lisa Ricciardi has been appointed CEO of Cambridge, MA-based Suono Bio. Founding CEO Carl Schoellhammer will shift to chief operating officer and board member. Ricciardi’s experience includes various roles at companies such as Pfizer (NYSE: [[ticker:PFE]]), Medco, and Foundation Medicine. Suono, an MIT spinout, is developing technology that uses ultrasound to improve drug delivery.
Allogene Files for IPO to Fund Cancer Cell Therapy Clinical Trials
Allogene Therapeutics, a biotech developing a cell therapy made from donor cells, is laying out IPO plans to finance more tests of its experimental cancer treatment. South San Francisco, CA-based Allogene made waves this year when it launched with a huge $300 million Series A round. It has now set a preliminary $100 million IPO … Continue reading “Allogene Files for IPO to Fund Cancer Cell Therapy Clinical Trials”
Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More
The long-running patent feud over CRISPR-Cas9 gene editing appears to be over, just as U.S. biotech companies gear up for the first human tests of the landmark technology. This week, a federal appeals court upheld a previous ruling handing a CRISPR-Cas9 patent to the Broad Institute of MIT and Harvard. The decision by the three-judge … Continue reading “Bio Roundup: CRISPR Ruling, “America’s Nobels,” IPOs & More”
Xconomy’s San Francisco Event to Showcase Biotech’s Next Generation
The life sciences and biomedicine are a constant field of tension between cutting-edge ideas and breakthroughs, and time-tested procedures and regulations guided by experience and concerns for safety. This tension is, on the whole, a good thing, helping innovators hone their ideas and strategies. At times like these, there are no shortage of scientific breakthroughs … Continue reading “Xconomy’s San Francisco Event to Showcase Biotech’s Next Generation”
Gilead Partners with Precision Bio in Search of Gene-Editing HBV Cure
Gilead Sciences is turning to gene editing in its effort to develop a cure for hepatitis B virus infections—DNA-cutting enzymes that would eliminate the virus in the body, something current hep B drugs can’t do. Foster City, CA-based Gilead (NASDAQ: [[ticker:GILD]]) is partnering with Precision Biosciences, a company that has used its proprietary gene-editing platform … Continue reading “Gilead Partners with Precision Bio in Search of Gene-Editing HBV Cure”
Andrew Cheng Departs Gilead Sciences for Akero Therapeutics CEO Post
Andrew Cheng has been appointed president and CEO of Cambridge, MA-based Akero Therapeutics. Cheng comes to Akero following a nearly 20-year career at Foster City, CA-based Gilead Sciences (NASDAQ: [[ticker:GILD]]), where he was most recently chief medical officer and executive vice president. Cheng will be based in San Francisco, which will be the location for … Continue reading “Andrew Cheng Departs Gilead Sciences for Akero Therapeutics CEO Post”
Ampio Pharma Chief Scientific Officer David Bar-Or to Retire
David Bar-Or, chief scientific officer of Ampio Pharmaceuticals (NYSE MKT: [[ticker:AMPE]]) will retire, effective Sept. 30. The Englewood, CO, company says Bar-Or will keep his positions on the board of directors and scientific advisory board. Ampio is preparing to file for FDA approval of aspartyl-alanyl diketopiperazine (Ampion), a treatment for osteoarthritis.
Aileron Therapeutics Promotes Manuel Aivado to CEO
Manuel Aivado has been appointed president and CEO of Aileron Therapeutics (NASDAQ: [[ticker:ALRN]]). He has also been elected to the Watertown, MA-based company’s board of directors. Aivado, who was Aileron’s chief medical and scientific officer, joined the company in 2014. Aileron started looking for a new CEO in May, after Joseph Yanchik suddenly resigned after … Continue reading “Aileron Therapeutics Promotes Manuel Aivado to CEO”
BMS Veteran Luisa Salter-Sid Named Gossamer Chief Scientific Officer
Luisa Salter-Cid has joined Gossamer Bio as the San Diego company’s chief scientific officer. Salter-Cid comes to Gossamer from Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), where she held various positions over the past 13 years, including vice president and head of immunology, small molecule immuno-oncology, and genomics discovery. Gossamer formed in January to in-license and develop drugs … Continue reading “BMS Veteran Luisa Salter-Sid Named Gossamer Chief Scientific Officer”
Kodiak Sciences Files for IPO to Fund Global AMD Eye-Drug Studies
Many patients with the more severe form of age-related macular degeneration, a type of vision loss, have trouble with the standard treatment—a once-monthly injection into the eye. Kodiak Sciences believes it can do better with an experimental drug that may require less frequent injections and the company has filed for an IPO to finance a … Continue reading “Kodiak Sciences Files for IPO to Fund Global AMD Eye-Drug Studies”
Akcea to Cut Staff 10% in Wake of FDA Rejection of Rare Disease Drug
Akcea Therapeutics is laying off 10 percent of its workforce, a move that follows the FDA’s rejection of the company’s rare disease drug last week. Cambridge, MA-based Akcea (NASDAQ: [[ticker:AKCA]]) said in a regulatory filing Thursday that the board of directors approved the reorganization plan on Sept. 2. Affected employees were notified Thursday. As of … Continue reading “Akcea to Cut Staff 10% in Wake of FDA Rejection of Rare Disease Drug”